Clinical Efficacy and Adverse Reactions of Antipsychotic Treatment

Schizophrenia Clinical Trial

Official title: Predictive Models of Clinical Efficacy and Adverse Reactions of Antipsychotic Treatment

Status Completed

Clinical Trial Summary

The goal of this clinical trial is to explore the potential of metformin in managing olanzapine-induced metabolic disturbance and hyperprolactinemia in patients with schizophrenia. The main questions it aims to answer are:

1. The effect of metformin on olanzapine-induced metabolic disturbance

2. The effect of metformin on olanzapine-induced hyperprolactinemia

Participants will receive metformin 1500 mg/day for 8 weeks and assessments every 2 weeks.

Clinical Trial Description

The study was conducted in an inpatient setting, with the dosage of olanzapine remaining consistent throughout the study duration. All participants were administered 1500 mg/day of metformin for eight weeks. Vital signs were measured daily. Physical and neurological examinations were carried out on a weekly basis. Every two weeks, all participants underwent an assessment for general psychopathology. Blood samples were collected in the morning after an overnight fast at the beginning of the study and then every two weeks following the commencement of metformin treatment. Serum prolactin levels were determined through electrochemiluminescence immunoassays. Fasting serum levels of glucose, total cholesterol, high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), and triglycerides were measured using enzymatic colorimetric assays. Serum insulin and leptin levels were measured using electrochemiluminescence immunoassay kits. ;

Related Conditions & MeSH terms

• Hyperprolactinemia
• Metabolic Disturbance
• Schizophrenia

• NCT number: NCT06326840
• Study type: Interventional
• Source: Taipei Medical University Hospital
• Status: Completed
• Phase: N/A
• Start date: May 31, 2010
• Completion date: June 10, 2011